Ene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004;64(19):6883?891. 38. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced illness stage. Science. 1984;224(4653):1121?124. 39. Valentijn LJ, Koppen A, van Asperen R, Root HA, Haneveld F, Versteeg R. Inhibition of a new differentiation pathway in neuroblastoma by copy quantity defects of N-myc, Cdc42, and nm23 genes. Cancer Res. 2005;65(eight):3136?145. 40. Kelsh RN. Sorting out Sox10 functions in neural crest development. Bioessays. 2006;28(8):788?98. 41. Gershon TR, Oppenheimer O, Chin SS, Gerald WL. Temporally regulated neural crest transcription components distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia. 2005;7(six):575?84. 42. Sato A, et al. FGF8 signaling is chemotactic for cardiac neural crest cells. Dev Biol. 2011;354(1):18?0. 43. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: principal adrenal tumor development and spontaneous distant metastasis. In Vivo. 2002; 16(2):77?5. 44. Wesche J, Haglund K, Haugsten EM. Fibroblast growth variables and their receptors in cancer. Biochem J. 2011;437(two):199?13. 45. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFRmediated carcinogenesis. Biochim Biophys Acta. 2012;1823(four):850?60. 46. Kakodkar NC, et al. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor development.Methanesulfonohydrazide Data Sheet Pediatr Blood Cancer. 2012;59(four):642?47. 47. Hahn CK, et al. Expression-based screening identifies the mixture of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A. 2008; 105(28):9751?756. 48. Tsang KS, et al. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts utilizing flow cytometry and reverse transcriptase-polymerase chain reaction.261522-33-2 Chemical name Cancer. 2003;97(11):2887?897. 49. Zeltzer PM, Marangos PJ, Evans AE, Schneider SL. Serum neuron-specific enolase in youngsters with neuroblastoma. Relationship to stage and illness course. Cancer. 1986;57(6):1230?234. 50. Riley RD, et al. A systematic overview of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;ten(1 pt 1):four?two. 51. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An important heparin-binding domain within the fibroblast development factor receptor kinase.PMID:23537004 Science. 1993;259(5103):1918?921. 52. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization techniques for higher density oligonucleotide array data primarily based on variance and bias. Bioinformatics. 2003; 19(two):185?93. 53. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level information. Nucleic Acids Res. 2003; 31(four):e15. 54. Pei Y, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012;21(2):155?67. 55. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression information working with empirical Bayes methods. Biostatistics. 2007;eight(1):118?27. 56. Dong M, et al. The form III TGF-beta receptor suppresses breast cancer progression. J Clin Invest. 2007;117(1):206?17. 57. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The kind III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007; 67(three):1090?098. 58. Boergermann JH, Kopf J, Y.